Back to EZorb Newsletter Index

 

EZorb

  

EZORB MONTHLY NEWSLETTER MAR 28, 2016

In this issue:

 

1. Share Success: Letters From Readers
2. Research News: Diabetes Medications May Benefit MS Patients
3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb and Marvlix?
  

1. Share Success: Letters From Readers 

***************************************************

Letter I: From Dolores R.

Received at sharesuccess @ ezorbonline.com Friday, August 28, 2015 9:09 AM

(Unedited)

 

I want to give you the good report that the bone spur in my left heel was so terrible that I could not walk.

After learning about E-Zorb and Marvlix (March, 2015) as well and taking it for three and a half months I started getting relief. As of this note to you it has been six months and I am walking normally!

I have always believed our Saviour Jesus Christ, has given us all we need to be well. So I thank Him for the natural cures He has supplied.

Respectfully,
Dolores Riney


Letter II: From Dorothy B.

Received at sharesuccess @ ezorbonline.com 08/27/15 at 9:39 AM

(Unedited)

 

Hello,

I want to let you know that my grandson's arm healed very well. The Dr. commented that the bone density healing was greater than he usually sees.

His Mom included the Ezorb as per your directions along with his usual supplements.

He is back in his sports full swing. And I pray for no more injuries, however have Ezorb handy in case!

Thank you again
Dorothy


Letter III: From Susan A.

Received at sharesuccess @ ezorbonline.com 08/01/15 at 1:04 PM

(Unedited)

 

Hi my name is Susan and I was suffering with Heel Spur for a while.

I went on the net to see what can help me with pain. EZorb newsletter popped up. I was so happy in reading those result. I went ahead and I called them. The guys who answered the phone was very nice and explained every thing to me.

I took a chance and I took it for three months. It really worked for me and am sure it will work for others. You can always try things to see how it works. If not you will never know what is best for you.

Doctors don't tell you all the good things what we can take because no matter they want us to come to them regularly and make they Money.

My pain is gone and I can walk freely.

Sent from my iPad Susan


Letter IV: From Joyce P.

  

Received at Testimonial Submit Form Sunday, August 9, 2015 1:36 PM

(Unedited)

 

I just want to share what happened to me. I was walking my dog and I fell on broken sidewalk. I fell on my left side my arm and shoulder were bruised and my knee had a big chunk of skin missing. It bleed very hard but then stopped.

I went to the hospital and had to have 5 stitches in it. The doctor xrayed it and nothing was broke or no tendons harmed.

I am 77 yrs young. I have been taking ezorb for about 3 yrs or more. I know the ezorb is working. Also my arm and shoulder were fine except for a few bruises.

Amen
Joyce P.


***************************************************

From the Desk of EZorb Newsletter Editor:

 
This newsletter is now read by over 95,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's quality of life. Your continuous support will be greatly appreciated by tens of thousands who have been suffering and would continuously suffer, without your help! Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public.


2. Research News: Diabetes Medications May Benefit MS Patients

 

Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis (MS) and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report.

They found that treatment with metformin or pioglitazone significantly decreased the number of new or enlarging T2 lesions or gadolinium-enhancing lesions after just 6 months, with benefits lasting for up to 2 years.

"This study is well in line with the recent growing interest in environmental risk factors associated with MS, in particular, those that are part of our daily habits such as diet", Aiden Haghikia and Ralf Gold, from Ruhr-University Bochum in Germany, comment in a related editorial.

For the open-label study, published in JAMA Neurology, 50 obese patients with MS who also developed metabolic syndrome underwent brain magnetic resonance imaging every 6 months following the initiation of metformin hydrochloride (850-1500 mg/day) in 20 patients and pioglitazone hydrochloride (15-30 mg/day) in 10 patients. The remaining 20 patients received neither treatment and served as controls.

After 2 years of treatment, the number of new or enlarging T2 lesions had decreased significantly from an average of 2.5 to 0.5 among patients taking metformin and from 2.3 to 0.6 among those given pioglitazone. Among controls, there was little change from the pre-treatment number of 2.4.

The drugs had a similar effect on gadolinium-enhancing lesions, the numbers of which decreased significantly after 2 years, from 1.8 before treatment to 0.1 with metformin and from 2.2 to 0.3 with pioglitazone.

This reduced inflammatory activity was accompanied by a significant suppression of levels of the proinflammatory adipokine leptin and a significant increase in the anti-inflammatory adipokine adiponectin with either treatment compared with none, note researcher Jorge Correale (Institute for Neurological Research Dr Raul Carrea, Buenos Aires, Argentina) and colleagues.

The mediating factors were AMP-activated protein kinase (AMPK) induction in the peripheral blood mononuclear cells in the case of metformin and peroxisome proliferator-activated receptor (PPAR)y induction in the case of pioglitazone.

Increased AMPK expression resulting from metformin treatment was associated with a significant decrease in the numbers of cells producing interferon y and interleukin (IL)-17. Meanwhile, PPARy induction with pioglitazone was associated with a significant decrease in the number of cells producing IL-6 and tumour necrosis factor.

With either drug, there was a robust increase in CD4+CD25+FoxP3+ regulatory T (Treg) cells, which in reduced numbers contribute to a chronic inflammatory state in obese individuals, the researchers note.

"Collectively, these observations provide both in vitro and in vivo evidence that metformin and pioglitazone treatment regulate immune and inflammatory responses and support recommendations of weight reduction in obese patients with MS", they conclude.

Original research was published in JAMA Neurol 2016; Advance online publication.


3. Useful Links

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

  

 

4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test @ elixirindustry.com for a copy of the instructions.

 

 

5. What Are Others Saying About EZorb and Marvlix?

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

   

Back to EZorb Newsletter Index

 
 
  Copyright 2016 Elixir Industry